Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
  • C07K1/14—Extraction; Separation; Purification
  • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
  • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
  • A61L2/0017—Filtration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to a process for producing a plasma protein composition free of viruses, particularly infectious viruses, in the plasma protein composition, a plasma protein composition substantially free of viruses, particularly infectious viruses, which is obtained by this method, a fibrinogen composition substantially free of non-enveloped viruses, particularly Parvovirus and/or hepatitis A virus, and to a method for removing viruses in a plasma protein composition.
• HAV human immunodeficiency virus
• HAV hepatitis A virus
• HBV hepatitis B virus
• HCV hepatitis C virus
• Fibrinogen is obtained from a fraction first precipitated during the process of alcohol plasma fractionation. Therefore, it is susceptible to the consequence of contamination once a virus invades plasma.
• Parvovirus B19 (hereinafter B19) is particularly drawing much attention lately. This virus does not have an envelope, is resistant to heat and has an extremely small single-particle size of about 18-25 nm, due to which properties its inactivation/removal is desired and is being investigated particularly in the field of plasma fractionation preparation.
• a method using a virus removal membrane is naturally capable of removing viruses having a greater molecule size than its pore size upon filtration, but otherwise when the virus is smaller in size than the pore size.
• the use of a removal membrane having too small a pore size results in clogging with a sample and the like, which makes filtration itself difficult.
• lower flow rates in parallel with the sample amounts during a membrane treatment give rise to many problems such as limited sample amount to be treated and a longer treatment time.
• the virus cannot be removed by a sole use of Planova 35N or Planova 75N (both trademarks, now commercially available porous membrane having a pore size of 35 nm or 75 nm, manufactured by Asahi Kasei Corporation), or even by a method using these virus removal membranes in multi-steps.
• Planova 35N or Planova 75N both trademarks, now commercially available porous membrane having a pore size of 35 nm or 75 nm, manufactured by Asahi Kasei Corporation
• the present inventors have conducted intensive studies in an attempt to solve these problems, and found that a porous membrane treatment affords efficient removal of contaminant viruses almost without losing the activity of protein, which resulted in the completion of the present invention.
• the present inventors have further found that a porous membrane treatment affords a fibrinogen composition substantially free of non-enveloped viruses, particularly Parvovirus and/or hepatitis A virus, which resulted in the completion of the present invention.
• the plasma protein in the plasma protein composition is not particularly limited and may be any as long as it is contained in blood.
• the plasma protein particularly capable of achieving the expected effect according to the method of the present invention has a high molecular weight and has a high risk of viral contamination.
• examples thereof include fibronectin, fibrinogen, coagulation factor V, coagulation factor VIII, von Willebrand Factor, coagulation factor XIII, retinol binding protein, ⁇ -globulin, ⁇ -globulin and ⁇ -globulin and the like.
• fibrinogen is obtained from a fraction first precipitated during the process of alcohol plasma fractionation, it is susceptible to viral contamination when a virus is mixed in plasma.
• removal of non-enveloped viruses by the convenient method of the present invention is useful.
• the plasma protein composition subject to the method of the present invention is free of any particular limitation as long as its viral contamination, particularly with infectious virus, is feared and a composition can be subjected to a porous membrane treatment.
• the composition is generally liquid, such as a solution containing fractions obtained from, for example, plasma or tissue extract by treatment according to various fractionation methods, culture liquid obtained by culture of genetically recombined host or tissue, commercially available protein preparation and the like.
• the precipitation method includes those known per se as protein fractionation methods. Examples thereof include precipitation methods using neutral salts (the precipitation method using the salts is what is called a salting-out method using sulfate, sulfite, thiosulfate, phosphate, alkali metal salt, ammonia, magnesium, halogen compound and the like), water-soluble organic solvents (e.g., ethanol, methanol, ethyl ether, acetone etc.), water-soluble non-ionized polymer compounds (e.g., polyethylene glycol (PEG), dextran, polyvinylpyrrolidone (PVP), nonylphenolethoxylate etc.), metal ions (e.g., barium sulfate, aluminum hydroxide etc.), organic cations (rivanol, protamine, other cationic surfactants etc.), anions (e.g., low molecular anion such as picric acid, trichloroacetic acid,
• glycine precipitation method when the protein is fibrinogen, glycine precipitation method is preferable, and glycine - sodium chloride precipitation method is more preferable.
• concentration of glycine is not lower than 50 g/L, preferably not lower than 75 g/L, and that of sodium chloride is 10 g/L, preferably not lower than 30 g/L.
• the upper limit is 250 g/L, preferably 225 g/L, for glycine, and 175 g/L, preferably 150 g/L, for sodium chloride.
• a porous membrane treatment refers to a filtration of plasma protein associated with the risk of virus contamination, through a porous membrane.
• the form of the membrane may be a hollow fiber, a sheet and the like, which is preferably a hollow fiber.
• a porous hollow fiber membrane made of regenerated cellulose can be prepared from a cupric ammonium solution of cellulose by a micro-phase separation method [Am. Chem. Soc., 9, 197-228 (1985)].
• the average pore size of the porous membrane to be used varies depending on the kind of protein and the kind of virus to be removed, it is generally 1-100 nm, preferably 10-100 nm.
• the pore size is 35-100 nm, preferably 35-75 nm, particularly when Parvovirus, HAV and the like are to be removed from a protein having a high molecular weight, such as fibrinogen and the like.
• the membrane is preferably in the form of a module.
• a number of porous hollow fiber membranes are bundled in parallel, fit in a cartridge and integrated with an adhesive to give a module.
• Planova series (trademark, manufactured by Asahi Kasei Corporation) having a multilayer structure comprising more than 100 layers of peripheral walls to be the membrane
• Viresolve series (trademark, manufactured by Millipore Corporation) known as a virus removal membrane
• Omega VR series (trademark, manufactured by Pall Corporation)
• Ultipor series (trademark, manufactured by Pall Corporation) and the like.
• Planova series Particularly preferred are Planova series.
• the filtration pressure is 10-100 kpa, preferably 10-90 kpa.
• the method of filtration includes crossflow filtration (circulation method), wherein the solution is filtered under a strain rate, and dead-end filtration (non-circulation method), wherein the solution is filtered without a strain rate.
• Preferred is dead-end filtration using pressurized air and the like.
• chaotropic ion or amino acid may be added to a sample. This allows enhanced expression of the effect of the present invention that contaminant viruses can be removed efficiently by a porous membrane treatment almost without losing the activity of protein.
• This filtration treatment may be applied once or more than once. Repeat treatment affords more superior virus removal effect upon filtration.
• the present invention treats a plasma protein composition with a porous membrane having a pore size greater than a single-particle size of the virus, whereby viruses having a single-particle size smaller than the pore size of a porous membrane can be removed.
• the plasma protein composition substantially free of the virus can be obtained.
• contaminant viruses can be removed efficiently almost without losing the activity of protein, and a plasma protein composition as a starting material of a safer plasma protein preparation can be provided.
• virus removed by the method of the present invention include vaccinia virus, mumps virus, herpes simplex virus, ECHO virus, Parvovirus, HIV, HAV, HBV, HCV, TTV and the like.
• non-enveloped virus associated with the risk of contamination include Parvovirus, HAV and the like.
• the plasma protein composition thus obtained can be used as it is, or is purified by a conventional protein purification method, such as PEG (polyethylene glycol) fractionation, alcohol fractionation, glycine fractionation, gel filtration, ion exchange chromatography, affinity chromatography, hydrophobic chromatography and the like and used as a plasma protein preparation.
• a conventional protein purification method such as PEG (polyethylene glycol) fractionation, alcohol fractionation, glycine fractionation, gel filtration, ion exchange chromatography, affinity chromatography, hydrophobic chromatography and the like and used as a plasma protein preparation.
• the plasma protein preparation is formed into a liquid preparation or dry preparation by a conventional method, which may contain, where necessary, a typical pharmacologically acceptable additive for a pharmaceutical agent, such as antiseptic, antibacterial, chelating agent, thickener, isotonizing agent and the like, or pharmaceutically necessary components.
• a typical pharmacologically acceptable additive for a pharmaceutical agent such as antiseptic, antibacterial, chelating agent, thickener, isotonizing agent and the like, or pharmaceutically necessary components.
• the production method of the present invention produces a plasma protein composition substantially free of viruses.
• the virus inactivation or removal methods generally employed such as dry heating, liquid heating, surfactant treatment, UV irradiation treatment, virus removal membrane treatment and the like, may be combined as appropriate before and after the method of the present invention, whereby the inactivation or removal of the virus can be made more complete.
• the substantially free of virus is meant being below the detection limit by a known virus measurement method.
• Parvovirus (10 2.7 copies/mL) was added as a monitor virus to the sample after the surfactant treatment.
• This sample was subjected to a fractionation treatment by precipitation using 15% glycine - 1M sodium chloride, and fibrinogen was precipitated by centrifugation (4,000 rpm, 20 min) and recovered.
• the recovered fibrinogen was dissolved in 1.0 L of citrate buffer solution to give a 1.0% solution. This solution was used as a sample before filtration and its virus amount was measured.
• This solution was subjected to a dead-end filtration using Planova 75N (average pore size 72 ⁇ 4 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• Parvovirus (10 5.7 copies/mL) was added as a monitor virus to this solution.
• this sample was subjected to a fractionation treatment using 15% glycine - 1M sodium chloride, and fibrinogen was precipitated by centrifugation (4,000 rpm, 20 min) and recovered.
• the recovered fibrinogen was dissolved in 1.0 L of citrate buffer solution to give a 1.0% solution. This solution was used as a sample before filtration and its virus amount was measured.
• the obtained solution was subjected to a dead-end filtration using Planova 75N (average pore size 72 ⁇ 4 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• Parvovirus was added as a monitor virus to the sample after the surfactant treatment.
• This sample was subjected to a fractionation treatment by precipitation using 15% glycine - 1M sodium chloride, and fibrinogen was precipitated by centrifugation (4,000 rpm, 20 min) and recovered.
• the recovered fibrinogen was dissolved in 1.0 L of citrate buffer solution to give a 1.0% solution.
• This solution was used as a sample before filtration and its virus amount was measured.
• this solution was taken as a sample before filtration and absorbance at 280 nm was measured to determine its protein amount.
• This solution was subjected to a dead-end filtration using Planova 75N (average pore size 72 ⁇ 4 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• absorbance at 280 nm was measured to determine the protein amount of this filtrate.
• This filtrate was subjected to a dead-end filtration using Planova 35N (average pore size 35 ⁇ 2 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• absorbance at 280 nm was measured to determine the protein amount of this filtrate.
• This sample was subjected to a fractionation treatment by precipitation using 8% glycine - 1M sodium chloride, and fibrinogen was precipitated by centrifugation (4,000 rpm, 20 min) and recovered.
• the recovered fibrinogen was dissolved in 1.5 L of water for injection to give a fibrinogen solution.
• the insoluble material in this solution was removed by a centrifugation treatment and sodium chloride (0.9 g/L) was added. This solution was used as a sample before filtration.
• This solution was subjected to a dead-end filtration using Planova 35N (average pore size 35 ⁇ 2 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• This sample was subjected to a fractionation treatment by precipitation using 8% glycine - 1M sodium chloride, and fibrinogen was precipitated by centrifugation (4,000 rpm, 20 min) and recovered.
• the recovered fibrinogen was dissolved in 1.5 L of water for injection to give a fibrinogen solution.
• the insoluble material in this solution was removed by a centrifugation treatment and sodium chloride (0.9 g/L) was added. This solution was used as a sample before filtration.
• This solution was subjected to a dead-end filtration using Planova 35N (average pore size 35 ⁇ 2 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• This sample was subjected to a fractionation treatment by precipitation using 15% glycine - 1M sodium chloride, and fibrinogen was precipitated and recovered.
• the recovered fibrinogen was dissolved in 1.0 L of citrate buffer solution to give a 1.0% solution.
• Parvovirus (10 10.7 copies/mL) was added as a monitor virus to this solution.
• This solution was used as a sample before filtration and its virus amount was measured.
• This solution was subjected to a dead-end filtration using Planova 75N (average pore size 72 ⁇ 4 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• This sample was subjected to a fractionation treatment by precipitation using 15% glycine - 1M sodium chloride, and fibrinogen was precipitated and recovered.
• the recovered fibrinogen was dissolved in 1.0 L of citrate buffer solution to give a 1.0% solution.
• Parvovirus (10 5.7 copies/mL) was added as a monitor virus to this solution.
• This solution was subjected to a dead-end filtration using Planova 75N (average pore size 72 ⁇ 4 nm) at a temperature of 23°C and a filtration pressure of 10 kpa to remove viruses.
• the filtrate was used as a sample after filtration and its virus amount was measured.
• the infectivity titer of EMC virus for Vero cells falls below detection limit at 10 1.5 TCID 50 /ml.
• the present invention by subjecting a plasma protein composition to a porous membrane treatment, contaminant viruses in the plasma protein can be removed efficiently almost without losing the activity of protein. Accordingly, the present invention provides a plasma protein free of a risk of viral infection. Particularly, by the porous membrane treatment of the present invention, a fibrinogen composition substantially free of non-enveloped viruses, Parvovirus and/or hepatitis A virus among others, can be provided.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Virology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Pulmonology (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Biotechnology (AREA)
• Water Supply & Treatment (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=18471588

Family Applications (1)

Country Status (8)

Cited By (5)

Families Citing this family (8)

Citations (3)

Family Cites Families (14)

• 2000
  • 2000-12-20 CA CA002394797A patent/CA2394797A1/fr not_active Abandoned
  • 2000-12-20 KR KR1020027007917A patent/KR20020063597A/ko not_active Application Discontinuation
  • 2000-12-20 WO PCT/JP2000/009057 patent/WO2001045719A1/fr active Application Filing
  • 2000-12-20 EP EP00987665A patent/EP1250929A4/fr not_active Withdrawn
  • 2000-12-20 US US10/168,180 patent/US6867285B2/en not_active Expired - Lifetime
  • 2000-12-20 CN CNB008174687A patent/CN1192781C/zh not_active Expired - Fee Related
  • 2000-12-20 AU AU23988/01A patent/AU2398801A/en not_active Abandoned
  • 2000-12-20 JP JP2001546658A patent/JP5080713B2/ja not_active Expired - Lifetime
• 2009
  • 2009-04-16 AU AU2009201499A patent/AU2009201499B8/en not_active Ceased

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events